|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.83 USD | -0.23% |
|
+0.03% | +12.85% |
| Dec. 16 | Harmony Biosciences, Beacon Biosignals Collaborate on Phase 3 Trials in Narcolepsy, Hypersomnia | MT |
| Dec. 16 | Beacon Biosignals announces partnership with Harmony Biosciences | RE |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Revenues | 160M | 305M | 438M | 582M | 715M | ||
Total Revenues | 160M | 305M | 438M | 582M | 715M | ||
Cost of Goods Sold, Total | 27.74M | 55.52M | 83.48M | 121M | 157M | ||
Gross Profit | 132M | 250M | 354M | 461M | 558M | ||
Selling General & Admin Expenses, Total | 95.57M | 132M | 163M | 193M | 221M | ||
R&D Expenses | 19.45M | 30.37M | 70.89M | 76.06M | 146M | ||
Other Operating Expenses, Total | 115M | 162M | 234M | 269M | 367M | ||
Operating Income | 16.99M | 87.53M | 120M | 192M | 191M | ||
Interest Expense, Total | -28.22M | -23.97M | -18.8M | -23.76M | -17.5M | ||
Interest And Investment Income | - | - | 3.13M | 14.73M | 18.54M | ||
Net Interest Expenses | -28.22M | -23.97M | -15.67M | -9.03M | 1.05M | ||
Other Non Operating Income (Expenses) | -3.07M | 16K | 169K | 159K | -68K | ||
EBT, Excl. Unusual Items | -14.3M | 63.57M | 105M | 183M | 192M | ||
Other Unusual Items | -22.64M | -26.15M | - | -9.77M | - | ||
EBT, Incl. Unusual Items | -36.94M | 37.43M | 105M | 173M | 192M | ||
Income Tax Expense | - | 2.83M | -76.78M | 44.54M | 46.31M | ||
Earnings From Continuing Operations | -36.94M | 34.6M | 181M | 129M | 145M | ||
Net Income to Company | -36.94M | 34.6M | 181M | 129M | 145M | ||
Net Income - (IS) | -36.94M | 34.6M | 181M | 129M | 145M | ||
Preferred Dividend and Other Adjustments | 26.9M | - | - | - | - | ||
Net Income to Common Incl Extra Items | -63.85M | 34.6M | 181M | 129M | 145M | ||
Net Income to Common Excl. Extra Items | -63.85M | 34.6M | 181M | 129M | 145M | ||
Per Share Items | |||||||
Net EPS - Basic | -2.48 | 0.6 | 3.07 | 2.17 | 2.56 | ||
Basic EPS - Continuing Operations | -2.48 | 0.6 | 3.07 | 2.17 | 2.56 | ||
Basic Weighted Average Shares Outstanding | 25.77M | 57.53M | 59.17M | 59.47M | 56.89M | ||
Net EPS - Diluted | -2.48 | 0.58 | 2.97 | 2.13 | 2.51 | ||
Diluted EPS - Continuing Operations | -2.48 | 0.58 | 2.97 | 2.13 | 2.51 | ||
Diluted Weighted Average Shares Outstanding | 25.77M | 59.21M | 61.1M | 60.37M | 57.87M | ||
Normalized Basic EPS | -0.35 | 0.69 | 1.11 | 1.92 | 2.11 | ||
Normalized Diluted EPS | -0.35 | 0.67 | 1.07 | 1.9 | 2.07 | ||
Supplemental Items | |||||||
EBITDA | 27.22M | 106M | 144M | 216M | 215M | ||
EBITA | 26.83M | 106M | 143M | 216M | 215M | ||
EBIT | 16.99M | 87.53M | 120M | 192M | 191M | ||
EBITDAR | 27.91M | 108M | 145M | 218M | 217M | ||
Effective Tax Rate - (Ratio) | - | 7.56 | -73.34 | 25.69 | 24.14 | ||
Current Domestic Taxes | - | 2.83M | 9.16M | 57.96M | - | ||
Total Current Taxes | - | 2.83M | 9.16M | 57.96M | 74.31M | ||
Deferred Domestic Taxes | - | 0 | -85.94M | -13.42M | - | ||
Total Deferred Taxes | - | 0 | -85.94M | -13.42M | -28M | ||
Normalized Net Income | -8.94M | 39.73M | 65.43M | 114M | 120M | ||
Interest on Long-Term Debt | 28.62M | 24.19M | 18.8M | 23.76M | 17.5M | ||
Supplemental Operating Expense Items | |||||||
Advertising Expense | 13.3M | 19.56M | 22.43M | 21.54M | 27.56M | ||
Selling and Marketing Expenses | 55.82M | 68.12M | 79.28M | 97.4M | 111M | ||
General and Administrative Expenses | 39.75M | 63.91M | 84.02M | 95.29M | 110M | ||
Research And Development Expense From Footnotes | 31.29M | 30.37M | 70.89M | 78.32M | 163M | ||
Net Rental Expense, Total | 686K | 1.2M | 1.53M | 1.81M | 2.1M | ||
Imputed Operating Lease Interest Expense | 1.06M | 1.18M | 1.18M | 1.76M | 1.56M | ||
Imputed Operating Lease Depreciation | -374K | 15.24K | 349K | 47.38K | 542K | ||
Stock-Based Comp., R&D Exp. (Total) | 586K | 2.12M | 2.61M | 3.96M | 6.68M | ||
Stock-Based Comp., S&M Exp. (Total) | 703K | 3.1M | 3.89M | 5.15M | 7.44M | ||
Stock-Based Comp., G&A Exp. (Total) | 3.9M | 10.88M | 20.4M | 22.1M | 28.58M | ||
Stock-Based Comp., Other (Total) | - | - | - | 499K | - | ||
Total Stock-Based Compensation | 5.19M | 16.1M | 26.9M | 31.7M | 42.7M |
Select your edition
All financial news and data tailored to specific country editions
















